Viewing nowCombinationPamikaz Tablets 10/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Korea Pharma

MFDS item code 201405515 · Approved 2014.11.25 · Insurance code 653005490
Treatment of essential hypertension not controlled by monotherapy
Amlodipine or Olmesartan Medoxomil are used in patients with essential hypertension when blood pressure is poorly controlled. They act by dilating blood vessels to lower blood pressure and help prevent cardiovascular complications. Often, this medication is used in combination when monotherapy is insufficient to enhance the therapeutic effect. It plays an important role in managing the patient's blood pressure steadily to maintain health. Thus, it is used for the treatment of essential hypertension.
Administer 1 tablet of this medicine once daily with water, with or without food. It is recommended to take it at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine must not be administered to patients with severe hepatic impairment. (See section 2, Patients who must not be administered this medicine, under Precautions for Use.) ∘ Older adults: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
∘ Children: The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established.
This drug can cause serious injury or death to the fetus and newborn, particularly during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Those allergic to this drug's active ingredients or similar components, pregnant or breastfeeding women, patients with severe liver disease or certain heart conditions, patients on kidney dialysis, those in a state of shock, and specific diabetic patients should not take this drug. In patients with low blood pressure due to a lack of fluid or salt, symptoms of low blood pressure may occur, so it is essential to closely monitor the condition upon first administration, and proper treatment is needed if low blood pressure occurs. This drug has a vasodilatory effect, so caution is required when used in patients with aortic stenosis, severe obstructive coronary artery disease, or congestive heart failure. For patients with impaired kidney function, this drug may affect kidney function, so regular monitoring of kidney function is necessary. In patients with liver impairment, metabolism and excretion of this drug may be delayed, requiring careful administration. During treatment with this drug, adverse reactions such as dizziness, headache, hypotension, edema, indigestion, skin rash, and others may occur, and if symptoms are severe or persistent, consultation with a physician is advised. This drug may interact with other medications, so if other medications are being taken, patients must inform their healthcare provider, and it is especially recommended to avoid taking it with grapefruit juice. It is safest not to take this drug during pregnancy, and for breastfeeding mothers, it is recommended to either discontinue breastfeeding or stop taking the medication as it may be passed into breast milk. Children under 18 years of age should not use this drug as its safety and efficacy have not been established. In the elderly, dosages may need to be adjusted and closely monitored considering the potential for reduced kidney and liver function. In cases of overdose, severe hypotension, vascular dilation, and tachycardia may occur, requiring immediate medical treatment and continuous monitoring of blood pressure and heart function. This drug should be stored in a closed container away from direct sunlight and moisture, and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a sealed container to prevent exposure to air or moisture. The storage temperature should ideally be maintained between 1 and 30 degrees Celsius at room temperature.
Reddish-brown round film-coated tablets
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Korea Pharma
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.